Physician profile
Marc M Dunn
NPI 1427002484
$15,802.30
in general payments reported to CMS, 2019-2025
48 companies · $3,053 in 2025
The $3,053 reported for 2025 was more than what 83% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,894 · 2020: $1,600 · 2021: $2,099 · 2022: $2,989 · 2023: $2,489 · 2024: $1,677 · 2025: $3,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,205 · Education: $14.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,205.37 |
| Education | $14.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,879.28 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $2,818.77 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,270.86 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Mylan Specialty L.P. | $914.90 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $790.12 | 2019-2025 | Dupixent |
| Grifols USA, LLC | $681.11 | 2019-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $637.78 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $550.79 | 2020-2025 | Glassia |
| Actelion Pharmaceuticals US, INC. | $466.08 | 2019-2025 | Opsumit, Uptravi |
| Insmed, INC. | $369.64 | 2019-2025 | Arikayce, Brinsupri |
| United Therapeutics Corporation | $351.32 | 2021-2025 | Tyvaso, Tyvaso |
| Verona Pharma, INC. | $341.97 | 2025 | Ohtuvayre |
| Baxter Healthcare | $261.84 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Inogen, INC. | $229.81 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth, Inogen |
| Pulmonx Corporation | $204.28 | 2021-2025 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.